Epistem, the UK biotechnology and personalised medicine company is to colllaborate with global pharmaceutical company sanofi-aventis US in a three-year deal worth up to $4 million.
Under the terms of the agreement Manchester-based Epistem will provide discovery through to clinical biomarker support to oncology programmes of sanofi-aventis and its affiliates.
Epistem may receive up to $4 million in research support payments including reimbursement of certain costs, over the 3 year period.
The collaboration is expected to inform sanofi-aventis oncology programmes with a biomarker strategy aimed at identifying biological responses to drugs in relevant tissues. The translational nature of this relationship means activities will cover preclinical, ex vivo and clinical support.
Matthew Walls Chief Executive Officer of Epistem said “We are excited at the prospect of working across a range of oncology programmes and of applying our technology in collaboration with the team at sanofi-aventis. This collaboration represents an important milestone for the Company as we continue to exploit our biomarker technologies which are well positioned to support and streamline the drug development process.”